Larimar Therapeutics appoints Russell Clayton as CMO, 180K stock option inducement grant

Larimar Therapeutics, Inc.

Russell 'Rusty' Clayton appointed Chief Medical Officer effective July 17, 2023, succeeding Nancy M. Ruiz (retiring).
Dr. Clayton previously served as Principal at Aeremedea, LLC and as advisor to Larimar for 5 years.
Inducement award of 180,000 stock options granted under Nasdaq Listing Rule 5635(c)(4), vesting over 4 years.
Dr. Clayton brings ~20 years of rare disease experience, including roles at Alcresta Therapeutics and Merck.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.